9 results on '"Kaluza V"'
Search Results
2. Technical Initial Problems and Automatic Transformation.
- Author
-
Kaluza, V., Kopriva, J., Kunovsky, J., and Sehnalova, P.
- Published
- 2009
- Full Text
- View/download PDF
3. Accuracy and Word Width in TKSL.
- Author
-
Kaluza, V., Kraus, M., Kunovsky, J., and Satek, V.
- Published
- 2008
- Full Text
- View/download PDF
4. dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp
- Author
-
Jackson, S.M., primary, Nakato, H., additional, Sugiura, M., additional, Jannuzi, A., additional, Oakes, R., additional, Kaluza, V., additional, Golden, C., additional, and Selleck, S.B., additional
- Published
- 1997
- Full Text
- View/download PDF
5. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
- Author
-
David, Schiff, Kurt A, Jaeckle, S Keith, Anderson, Evanthia, Galanis, Caterina, Giannini, Jan C, Buckner, Phillip, Stella, Patrick J, Flynn, Bradley J, Erickson, John F, Schwerkoske, Vesna, Kaluza, Erin, Twohy, Janet, Dancey, John, Wright, Jann N, Sarkaria, Schiff D., Jaeckle K.A., Anderson S.K., Galanis E., Giannini C., Buckner J.C., Stella P., Flynn P.J., Erickson B.J., Schwerkoske J.F., Kaluza V., Twohy E., Dancey J., Wright J., and Sarkaria J.N.
- Subjects
Sirolimus ,Adult ,Male ,Antineoplastic Combined Chemotherapy Protocol ,Maximum Tolerated Dose ,Brain Neoplasms ,Prognosi ,glioblastoma ,clinical trial ,temsirolimu ,Middle Aged ,Sorafenib ,Prognosis ,targeted therapy ,Article ,Follow-Up Studie ,Brain Neoplasm ,Survival Rate ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Sirolimu ,Neoplasm Recurrence, Local ,Follow-Up Studies ,Human - Abstract
BACKGROUND: Mitogen-activated protein kinase (MAPK) activation and mammalian target of rapamycin (mTOR)-dependent signaling are hallmarks of glioblastoma. In the current study, the authors conducted a phase 1/2 study of sorafenib (an inhibitor of Raf kinase and vascular endothelial growth factor receptor 2 [VEGFR-2]) and the mTOR inhibitor temsirolimus in patients with recurrent glioblastoma. METHODS: Patients with recurrent glioblastoma who developed disease progression after surgery or radiotherapy plus temozolomide and with ≤2 prior chemotherapy regimens were eligible. The phase 1 endpoint was the maximum tolerated dose (MTD), using a cohorts-of-3 design. The 2-stage phase 2 study included separate arms for VEGF inhibitor (VEGFi)–naive patients and patients who progressed after prior VEGFi. RESULTS: The MTD was sorafenib at a dose of 200 mg twice daily and temsirolimus at a dose of 20 mg weekly. In the first 41 evaluable patients who were treated at the phase 2 dose, there were 7 who were free of disease progression at 6 months (progression-free survival at 6 months [PFS6]) in the VEGFi-naive group (17.1%); this finding met the prestudy threshold of success. In the prior VEGFi group, only 4 of the first 41 evaluable patients treated at the phase 2 dose achieved PFS6 (9.8%), and this did not meet the prestudy threshold for success. The median PFS for the 2 groups was 2.6 months and 1.9 months, respectively. The median overall survival for the 2 groups was 6.3 months and 3.9 months, respectively. At least 1 adverse event of grade ≥3 was observed in 75.5% of the VEGFi-naive patients and in 73.9% of the prior VEGFi patients. CONCLUSIONS: The limited activity of sorafenib and temsirolimus at the dose and schedule used in the current study was observed with considerable toxicity of grade ≥3. Significant dose reductions that were required in this treatment combination compared with tolerated single-agent doses may have contributed to the lack of efficacy. Cancer 2018;124:1455-63. © 2018 American Cancer Society.
- Published
- 2018
6. A 77-year-old Woman with a Right Cerebellar Lesion.
- Author
-
Conway R, Kaluza V, Schwartz K, and Chang HT
- Subjects
- Aged, Cerebellar Neoplasms pathology, Cerebellum pathology, Female, Humans, Leukoencephalopathy, Progressive Multifocal diagnosis
- Published
- 2019
- Full Text
- View/download PDF
7. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572.
- Author
-
Schiff D, Jaeckle KA, Anderson SK, Galanis E, Giannini C, Buckner JC, Stella P, Flynn PJ, Erickson BJ, Schwerkoske JF, Kaluza V, Twohy E, Dancey J, Wright J, and Sarkaria JN
- Subjects
- Adult, Brain Neoplasms pathology, Female, Follow-Up Studies, Glioblastoma pathology, Humans, Male, Maximum Tolerated Dose, Middle Aged, Neoplasm Recurrence, Local pathology, Prognosis, Sirolimus administration & dosage, Sirolimus analogs & derivatives, Sorafenib administration & dosage, Survival Rate, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms drug therapy, Glioblastoma drug therapy, Neoplasm Recurrence, Local drug therapy
- Abstract
Background: Mitogen-activated protein kinase (MAPK) activation and mammalian target of rapamycin (mTOR)-dependent signaling are hallmarks of glioblastoma. In the current study, the authors conducted a phase 1/2 study of sorafenib (an inhibitor of Raf kinase and vascular endothelial growth factor receptor 2 [VEGFR-2]) and the mTOR inhibitor temsirolimus in patients with recurrent glioblastoma., Methods: Patients with recurrent glioblastoma who developed disease progression after surgery or radiotherapy plus temozolomide and with ≤2 prior chemotherapy regimens were eligible. The phase 1 endpoint was the maximum tolerated dose (MTD), using a cohorts-of-3 design. The 2-stage phase 2 study included separate arms for VEGF inhibitor (VEGFi)-naive patients and patients who progressed after prior VEGFi., Results: The MTD was sorafenib at a dose of 200 mg twice daily and temsirolimus at a dose of 20 mg weekly. In the first 41 evaluable patients who were treated at the phase 2 dose, there were 7 who were free of disease progression at 6 months (progression-free survival at 6 months [PFS6]) in the VEGFi-naive group (17.1%); this finding met the prestudy threshold of success. In the prior VEGFi group, only 4 of the first 41 evaluable patients treated at the phase 2 dose achieved PFS6 (9.8%), and this did not meet the prestudy threshold for success. The median PFS for the 2 groups was 2.6 months and 1.9 months, respectively. The median overall survival for the 2 groups was 6.3 months and 3.9 months, respectively. At least 1 adverse event of grade ≥3 was observed in 75.5% of the VEGFi-naive patients and in 73.9% of the prior VEGFi patients., Conclusions: The limited activity of sorafenib and temsirolimus at the dose and schedule used in the current study was observed with considerable toxicity of grade ≥3. Significant dose reductions that were required in this treatment combination compared with tolerated single-agent doses may have contributed to the lack of efficacy. Cancer 2018;124:1455-63. © 2018 American Cancer Society., (© 2018 American Cancer Society.)
- Published
- 2018
- Full Text
- View/download PDF
8. Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report.
- Author
-
Kaluza V, Rao DS, Said JW, and de Vos S
- Subjects
- Antimetabolites, Antineoplastic therapeutic use, Brain Neoplasms diagnosis, Brain Neoplasms diagnostic imaging, Brain Neoplasms drug therapy, Brain Neoplasms genetics, Brain Neoplasms pathology, CD3 Complex genetics, CD3 Complex metabolism, CD56 Antigen genetics, CD56 Antigen metabolism, DNA, Neoplasm analysis, Enoxaparin therapeutic use, Fatal Outcome, Fibrinolytic Agents therapeutic use, Genes, T-Cell Receptor gamma genetics, Granzymes, Humans, Lymphoma, T-Cell diagnosis, Lymphoma, T-Cell diagnostic imaging, Lymphoma, T-Cell drug therapy, Lymphoma, T-Cell genetics, Lymphoma, T-Cell pathology, Magnetic Resonance Imaging, Male, Methotrexate therapeutic use, Middle Aged, Pulmonary Embolism complications, Pulmonary Embolism drug therapy, RNA, Viral metabolism, Serine Endopeptidases genetics, Serine Endopeptidases metabolism, Tomography, X-Ray Computed, Tumor Virus Infections pathology, Brain Neoplasms metabolism, Killer Cells, Natural pathology, Lymphoma, T-Cell metabolism
- Abstract
Natural killer (NK)/T-cell lymphomas represent a rare type of lymphoma derived from either activated NK cells or, rarely, cytotoxic T cells. These lesions are most commonly extranodal and tend to present as destructive lesions within the midline facial structures. Other than the nasal cavity and paranasal sinuses, several other extranodal sites of involvement have been reported, including the pharynx, gastrointestinal tract, and testis. Although secondary involvement of the central nervous system has been reported, a convincing case of primary brain NK/T-cell lymphoma has not been previously reported. Here, we report a case of primary brain lymphoma of NK/T-cell type with a characteristic phenotype expressing CD3epsilon, CD56, granzyme B, Epstein-Barr virus-encoded small nuclear RNAs, with germline T-cell receptor gene configuration, and showing an unusual intravascular component. The patient underwent extensive imaging studies, revealing only the brain lesion. The lymphoma failed to respond to therapy and the patient eventually died after transfer to a hospice facility. This unusual case highlights an unusual presentation of a rare disease entity and highlights the need for a better understanding of the biology and treatment of T-cell lymphomas.
- Published
- 2006
- Full Text
- View/download PDF
9. The cell-surface proteoglycan Dally regulates Wingless signalling in Drosophila.
- Author
-
Tsuda M, Kamimura K, Nakato H, Archer M, Staatz W, Fox B, Humphrey M, Olson S, Futch T, Kaluza V, Siegfried E, Stam L, and Selleck SB
- Subjects
- Animals, Animals, Genetically Modified, Cloning, Molecular, Drosophila genetics, Epidermis embryology, Epidermis physiology, Female, Genes, Insect, Genetic Techniques, Genitalia embryology, Glycosylphosphatidylinositols chemistry, Glycosylphosphatidylinositols physiology, Heparan Sulfate Proteoglycans chemistry, Heparan Sulfate Proteoglycans physiology, Homeodomain Proteins physiology, Insect Proteins physiology, Larva chemistry, Male, Membrane Glycoproteins chemistry, Membrane Glycoproteins genetics, Mutation, Proteoglycans chemistry, Proteoglycans genetics, RNA metabolism, Transcription Factors physiology, Wnt1 Protein, Drosophila physiology, Drosophila Proteins, Membrane Glycoproteins physiology, Proteoglycans physiology, Proto-Oncogene Proteins physiology, Signal Transduction
- Abstract
Wingless (Wg) is a member of the Wnt family of growth factors, secreted proteins that control proliferation and differentiation during development. Studies in Drosophila have shown that responses to Wg require cell-surface heparan sulphate, a glycosaminoglycan component of proteoglycans. These findings suggest that a cell-surface proteoglycan is a component of a Wg/Wnt receptor complex. We demonstrate here that the protein encoded by the division abnormally delayed (dally) gene is a cell-surface, heparan-sulphate-modified proteoglycan. dally partial loss-of-function mutations compromise Wg-directed events, and disruption of dally function with RNA interference produces phenotypes comparable to those found with RNA interference of wg or frizzled (fz)/Dfz2. Ectopic expression of Dally potentiates Wg signalling without altering levels of Wg and can rescue a wg partial loss-of-function mutant. We also show that dally, a regulator of Decapentaplegic (Dpp) signalling during post-embryonic development, has tissue-specific effects on Wg and Dpp signalling. Dally can therefore differentially influence signalling mediated by two growth factors, and may form a regulatory component of both Wg and Dpp receptor complexes.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.